Condition (MeSH)
Intestinal Pseudo-Obstruction
ClinicalTrials.gov lists 27 trials for Intestinal Pseudo-Obstruction or a narrower condition beneath it. Furiex Pharmaceuticals, Inc has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 27 trials are tagged with Intestinal Pseudo-Obstruction itself; the rest are tagged with a narrower condition beneath it.
When did Intestinal Pseudo-Obstruction trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 3 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 2 |
| 2015 | 2 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Intestinal Pseudo-Obstruction trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 11 |
| Observational | 5 |
How many Intestinal Pseudo-Obstruction trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
| Completed | 14 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Intestinal Pseudo-Obstruction trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Furiex Pharmaceuticals, Inc | 2 |
Which drugs are being tested for Intestinal Pseudo-Obstruction? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Eluxadoline | 2 |
| Neostigmine | 1 |
| DEXMEDETOMIDINE | 1 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| gum chewing | 2 |
| Chewing Gum | 2 |
| Biopsy | 1 |
| Rifaximine | 1 |
| Sham Procedure | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Intestinal Pseudo-Obstruction trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pancreatitis acute | 4 | 2 |
| Chest pain | 2 | 1 |
| Abdominal discomfort | 1 | 1 |
| Acute coronary syndrome | 1 | 1 |
| Affective disorder | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Intestinal Pseudo-Obstruction? (58)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical Trial: Efficacy and Safety of Velusetrag in Chronic Intestinal Pseudo-Obstruction: A Randomized, Phase 2, Placebo-Controlled, Crossover, Multiple (nâ=â1), Proof-of-Concept Study. | Neurogastroenterology and motility | 2026 | Yes |
| The natural history of infantile mitochondrial DNA depletion syndrome due to RRM2B deficiency. | Genetics in medicine : official journal of the American College of Medical Genetics | 2020 | Yes |
| Recurrent arginine substitutions in the ACTG2 gene are the primary driver of disease burden and severity in visceral myopathy. | Human mutation | 2020 | Yes |
| Update on chronic intestinal pseudo-obstruction. | Current opinion in gastroenterology | 2020 | Yes |
| Stimulation the efferent limb before loop ileostomy closure with short chain fatty acids. | Cirugia espanola | 2019 | Yes |
Showing 5 of 58 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.